Eli Lilly & Co. (LLY): price, analyst ratings, earnings and fundamentals
Updated 30 October 2026, 21:45 ET
Eli Lilly & Co. (LLY) closed at $1,417.54 on 30 October 2026, up 3.2%. The stock is up 23.3% over one month and up 74.2% over one year. It trades 2.2% below its 52-week high of $1,449.68. Analysts recorded 19 actions in the last 90 days; the median price target of $1,425 is 0.5% above the last close. The company last reported on 29 October 2026 for Q3 2026: EPS of $7.48 against an estimate of $6.36, a beat of 17.6%, on revenue of $24.4 billion.
Price and performance
Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.
The live chart with technical indicators is in the app: open LLY in FundSpec.
Analyst ratings
Over the last 90 days FundSpec recorded 19 analyst actions on LLY from 13 firms: 19 maintained or reiterated a view. Price targets were 17 raised. The most recent targets from 19 firms range from $940 to $1,650, with a median of $1,425, 0.5% above the last close.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 30 Oct 2026 | JP Morgan | Maintains Overweight | $1,500.00 to $1,650.00 |
| 30 Oct 2026 | Citigroup | Maintains Buy | $1,600.00 to $1,650.00 |
| 30 Oct 2026 | Scotiabank | Maintains Sector Outperform | $1,300.00 to $1,605.00 |
| 30 Oct 2026 | Morgan Stanley | Maintains Overweight | $1,430.00 to $1,596.00 |
| 30 Oct 2026 | Wells Fargo | Maintains Overweight | $1,330.00 to $1,500.00 |
| 30 Oct 2026 | Truist Securities | Reiterates Buy | $1,376.00 to $1,612.00 |
| 30 Oct 2026 | RBC Capital | Maintains Outperform | $1,500.00 to $1,600.00 |
| 30 Oct 2026 | Argus Research | Maintains Buy | $1,300.00 to $1,550.00 |
| 21 Oct 2026 | Leerink Partners | Maintains Outperform | $1,309.00 to $1,316.00 |
| 12 Oct 2026 | RBC Capital | Reiterates Outperform | $1,500.00 |
A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.
Every action with the firm's history is in Analyst Ratings.
Earnings
The next report is scheduled for 3 February 2027 before the open for Q4 2026, with EPS expected at $10.99 on revenue of $24.4 billion. Eli Lilly & Co. beat the EPS estimate in 8 of its last 8 reported quarters.
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3 2026 | 29 Oct 2026 | $6.36 | $7.48 | +17.61% | $24.4B |
| Q2 2026 | 5 Aug 2026 | $6.01 | $8.38 | +39.43% | $23.0B |
| Q1 2026 | 30 Apr 2026 | $6.85 | $8.55 | +24.82% | $19.8B |
| Q4 2025 | 4 Feb 2026 | $6.96 | $7.54 | +8.33% | $19.3B |
| Q3 2025 | 30 Oct 2025 | $5.96 | $7.02 | +17.79% | $17.6B |
| Q2 2025 | 7 Aug 2025 | $5.60 | $6.31 | +12.68% | $15.6B |
| Q1 2025 | 1 May 2025 | $3.02 | $3.34 | +10.60% | $12.7B |
| Q4 2024 | 6 Feb 2025 | $5.08 | $5.32 | +4.72% | $13.5B |
An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.
Estimates, confirmed dates and alerts for every company are in Earnings.
Fundamentals
For the period ended 30 September 2026, Eli Lilly & Co. reported revenue of $24.4 billion and net income of $6.5 billion. On a trailing twelve month basis the company shows revenue growth of 45.51%, a gross margin of 83.63%, an operating margin of N.A. and a return on equity of 86.10%.
Income statement
| Line | Amount |
|---|---|
| Revenue | $24,397,000,000 |
| Cost of Revenue | $3,933,000,000 |
| Gross Profit | $20,464,000,000 |
| Selling, General & Administrative Expenses | $3,125,000,000 |
| Depreciation & Amortization | $545,000,000 |
| Pre-tax Income | $8,406,000,000 |
| Income Tax Expense | $1,955,000,000 |
| Net Income | $6,451,000,000 |
Cash flow
| Line | Amount |
|---|---|
| Cash from Operating Activities | $11,397,000,000 |
| Stock-based Compensation | $200,000,000 |
| Cash from Investing Activities | -$8,299,000,000 |
| Cash from Financing Activities | -$7,219,000,000 |
| Dividends Paid | $1,541,000,000 |
| Share Repurchases | $377,000,000 |
Assets
| Line | Amount |
|---|---|
| Cash & Cash Equivalents | $4,885,000,000 |
| Short-term Investments | $121,600,000 |
| Accounts & Notes Receivable, Net | $22,089,000,000 |
| Prepaid Expenses | $16,862,000,000 |
| Inventory | $18,194,000,000 |
| Other Current Assets | $91,000,000 |
| Total Current Assets | $65,263,000,000 |
| Plant, Property & Equipment, Net | $32,188,000,000 |
| Operating Lease Right-of-Use Assets | $1,260,000,000 |
| Long-term Investments | $4,013,000,000 |
| Goodwill Intangible Assets, Net | $27,958,000,000 |
| Deferred Tax Asset | $14,385,000,000 |
| Other Long-term Assets | $7,695,000,000 |
| Total Assets | $148,072,000,000 |
Liabilities and equity
| Line | Amount |
|---|---|
| Accounts Payable & Accrued Expenses | $5,793,000,000 |
| Operating Lease Liabilities, Current | $222,000,000 |
| Other Current Liabilities | $12,224,000,000 |
| Total Current Liabilities | $46,996,000,000 |
| Long-term Debt | $46,986,000,000 |
| Operating Lease Liabilities, Long-term | $1,140,000,000 |
| Minority Interest | $57,500,000 |
| Other Borrowings | $339,000,000 |
| Other Liabilities | $7,749,000,000 |
| Total Liabilities | $107,743,500,000 |
| Common Stock | $588,000,000 |
| Retained Earnings | $37,969,000,000 |
| Treasury Stock | -$62,500,000 |
| Other Accumulated Comprehensive Income | -$2,629,000,000 |
| Total Stockholders Equity | $40,271,000,000 |
| Total Liability & Stockholders Equity | $148,072,000,000 |
Figures as filed with the SEC for the period ended 30 September 2026, in US dollars.
FundSpec fundamental metrics
Each metric is computed from the company's filings and ranked against every company FundSpec covers; the percentile is the share of covered companies with a lower value.
Liquidity
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Cash Ratio | 0.11 | 35th | Calculated as the ratio of Cash and cash equivalents / Current liabilities. This metric calculates the company's ability to repay its short-term debt |
| Current Ratio | 1.39 | 56th | Calculated as the ratio of Current Assets / Current Liabilities. The higher the current ratio, the more capable the company is of paying its obligations |
| Quick Ratio | 0.58 | 37th | Calculated as the ratio of (Cash + Marketable Securities + Accounts Receivable) / Current Liabilities. The quick ratio is a measure of how well a company can meet its short-term financial liabilities. |
Leverage
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Debt/Assets | 0.32 | 74th | Calculated as the ratio of Short-Term Debt + Long-Term Debt / Total Assets. The higher the ratio, the higher the degree of leverage, and consequently, financial risk |
| Debt/Equity | 1.17 | 79th | Calculated as the ratio of Total Liabilities / Shareholders' Equity. The ratio indicates how much debt a company is using to finance its assets relative to the amount of value represented in shareholders’ equity |
| Long Term Debt/Long Term Capital | 0.54 | 66th | Calculated as Long-Term Debt / (Long-Term Debt + Shareholders' Equity). The ratio is an indicator of the company's leverage |
| Long Term Debt/Total Capital | 0.54 | 73rd | Calculated as (Short-Term Debt + Long-Term Debt / (Short-Term Debt + Long-Term Debt + Shareholders' Equity). The ratio is an indicator of the company's leverage |
Profitability
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Gross Margin Pct | 83.6% | 92nd | Calculated as the ratio of Revenue - Cost of Goods Sold (COGS) / Revenue. The gross margin represents the percent of total sales revenue that the company retains after incurring the direct costs associated with producing the goods and services sold by a company. |
| PreTax Margin Pct | 40.2% | 92nd | Calculated as the ratio of (Gross profit - (Operating Expense + Interest Expense)) / Revenue. The pretax profit margin enables profitability to be compared across companies with significant differences in size, scale, capital structure and tax rates. |
| Return on Assets Pct | 21.0% | 96th | Calculated as the ratio of Net Income / Total Assets. It is an indicator of how efficient the company is at using its assets to generate earnings. |
| Return on Equity Pct | 86.1% | 98th | Calculated as the ratio of Net Income / Shareholders' equity. It is a measure of how much profit a company generates with the money shareholders have invested. |
Earnings Growth (Net Income)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Net Income Pct Growth | 49.8% | 72nd | The Net Income growth rate over the trailing twelve months (TTM) |
| Net Income Pct Growth 3 year CAGR | 76.8% | 97th | The Net Income compound annual growth rate (CAGR) over the past 3 years |
| Net Income Pct Growth 5 year CAGR | 35.8% | 92nd | The Net Income compound annual growth rate (CAGR) over the past 5 years |
Cashflow
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Operating Cashflow Pct Growth | 90.8% | 84th | The Operating Cashflow growth rate over the trailing twelve months (TTM) |
| Operating Cashflow Pct Growth 3 year CAGR (FY) | 70.2% | 96th | The Operating Cashflow compound annual growth rate (CAGR) over the past 3 years |
| Operating Cashflow Pct Growth 5 year CAGR (FY) | 34.7% | 92nd | The Operating Cashflow compound annual growth rate (CAGR) over the past 5 years |
Top Line Growth
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Revenue Pct Growth | 45.5% | 88th | The Revenue (Sales) growth rate over the trailing twelve months (TTM) |
| Revenue Pct Growth 3 year CAGR | 39.2% | 91st | The Revenue (Sales) compound annual growth rate (CAGR) over the past 3 years |
| Revenue Pct Growth 5 year CAGR | 25.5% | 87th | The Revenue (Sales) compound annual growth rate (CAGR) over the past 5 years |
Taxes
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Effective Tax Rate Pct | 20.7% | 69th | The effective tax rate of the company over the trailing twelve months (TTM). |
Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.
Fair value, peer multiples and the full statement history are in the app: open LLY in FundSpec.
Insider activity
In the last 90 days insiders filed 21 transactions: 12 acquisitions covering 108 shares. Acquisitions include awards and option exercises as well as open market purchases. The largest by value was a disposal of 6,500 shares by Patrik Jonsson, EVP & President, LLY Int'l on 17 August 2026, worth about $7.6 million at the transaction price.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 19 Oct 2026 | Juan R Luciano | Director | Acquisition | 13 | $1,240.34 | $16K |
| 19 Oct 2026 | Ralph Alvarez | Director | Acquisition | 10 | $1,240.34 | $12K |
| 19 Oct 2026 | J Erik Fyrwald | Director | Acquisition | 8 | $1,240.34 | $10K |
| 19 Oct 2026 | Gabrielle Sulzberger | Director | Acquisition | 4 | $1,240.34 | $5K |
| 21 Sep 2026 | Juan R Luciano | Director | Acquisition | 14 | $1,164.89 | $16K |
| 21 Sep 2026 | Ralph Alvarez | Director | Acquisition | 11 | $1,164.89 | $12K |
| 21 Sep 2026 | J Erik Fyrwald | Director | Acquisition | 9 | $1,164.89 | $10K |
| 21 Sep 2026 | Gabrielle Sulzberger | Director | Acquisition | 4 | $1,164.89 | $5K |
| 9 Sep 2026 | Melissa Seymour | EVP, Global Quality | G | 12 | ||
| 2 Sep 2026 | Edgardo Hernandez | EVP & Pres., Mfg. Operations | G | 13 | ||
| 2 Sep 2026 | Eric Dozier | EVP, Chief People Officer | G | 216 | ||
| 17 Aug 2026 | Patrik Jonsson | EVP & President, LLY Int'l | S | 6,500 | $1,175.10 | $7.6M |
| 17 Aug 2026 | Juan R Luciano | Director | Acquisition | 13 | $1,183.16 | $16K |
| 17 Aug 2026 | Ralph Alvarez | Director | Acquisition | 10 | $1,183.16 | $12K |
| 17 Aug 2026 | J Erik Fyrwald | Director | Acquisition | 8 | $1,183.16 | $10K |
Insider filings record what officers and directors did with their own shares. Disposals are often planned sales or tax related, so a pattern across several insiders says more than one filing.
SEC filings
The latest filing is a 10-Q from 29 October 2026.
| Filed | Form | Document |
|---|---|---|
| 29 Oct 2026 | 10-Q | View on sec.gov |
| 5 Aug 2026 | 10-Q | View on sec.gov |
| 30 Apr 2026 | 10-Q | View on sec.gov |
| 12 Feb 2026 | 10-K | View on sec.gov |
| 30 Oct 2025 | 10-Q | View on sec.gov |
| 7 Aug 2025 | 10-Q | View on sec.gov |
| 1 May 2025 | 10-Q | View on sec.gov |
| 19 Feb 2025 | 10-K | View on sec.gov |
| 30 Oct 2024 | 10-Q | View on sec.gov |
| 8 Aug 2024 | 10-Q | View on sec.gov |
Company profile
- Exchange
- NYSE
- Sector
- Pharmaceuticals, Biotech and Chemicals
- Industry
- Pharmaceutical Products
- Headquarters
- Indianapolis, Indiana
- Chief executive
- David A. Ricks
- Employees
- 39,000
- Website
- lilly.com
- SEC CIK
- 0000059478
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Sector and peers
Eli Lilly & Co. is part of the Pharmaceuticals, Biotech and Chemicals sector, which FundSpec tracks across 609 companies.
Companies in the same industry by market capitalization:
JNJ Johnson & JohnsonABBV AbbVie Inc.MRK Merck & Co. Inc.NVS Novartis AGAZN AstraZeneca PLCABT Abbott LaboratoriesPFE Pfizer Inc.VRTX Vertex Pharmaceuticals Inc.
Put two of them side by side in Compare.
FundSpec AI trading models
LLY is traded intraday by 1 FundSpec AI model whose verified winning calls FundSpec publishes.
| Model | Verified wins | Average gain | Best gain | Last win |
|---|---|---|---|---|
| Eli Lilly & Co. (LLY) day trading model | 136 | 0.58% | 1.82% | 30 Oct 2026 |
A day trading model learns an entry and exit policy for one stock from its intraday history. The record lists calls that closed with a gain; it is a track record, not a forecast. Read the guide: How FundSpec AI trading models work.
In FundSpec: the fair value estimate, the momentum reading, relative valuation against sector and industry peers, unusual options activity and AI model signals for LLY are available to subscribers, with the same screen in the iOS and Android apps.
Open LLY in FundSpec